- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
SAGE Therapeutics Inc (SAGE)
"SAGE Therapeutics Inc stock price live, this page displays NASDAQ SAGE stock exchange data. View the SAGE premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the SAGE Therapeutics Inc real time stock price chart below.
What Is the SAGE Therapeutics Inc Stock Price Today?
The SAGE Therapeutics Inc stock price today is 7.62.
What Is the Stock Symbol for SAGE Therapeutics Inc?
The stock symbol for SAGE Therapeutics Inc is ""SAGE.""
What Stock Exchange Does SAGE Therapeutics Inc Trade On?
SAGE Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is SAGE Therapeutics Inc a Good Stock to Buy?
Determining whether SAGE Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SAGE quote. (ISIN: US78667J1088)"
What Is the SAGE Therapeutics Inc Stock Price Today?
The SAGE Therapeutics Inc stock price today is 7.62.
What Is the Stock Symbol for SAGE Therapeutics Inc?
The stock symbol for SAGE Therapeutics Inc is ""SAGE.""
What Stock Exchange Does SAGE Therapeutics Inc Trade On?
SAGE Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is SAGE Therapeutics Inc a Good Stock to Buy?
Determining whether SAGE Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SAGE quote. (ISIN: US78667J1088)"
7.62
-0.06(-0.78%)
Closed·
Pre Market
7.41-0.21(-2.76%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.61
7.89
52 wk Range
4.62
14.97
SAGE Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 5 days
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.617.89
52 wk Range
4.6214.97
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
SAGE Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Neutral
Price Target
8.10
Upside
+6.32%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
- Sage Therapeutics CMO to leave for new opportunity
- Investing.com
- Sage Therapeutic receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Sage Therapeutic receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Sage Therapeutics announces CMO resignation
- Investing.com
SAGE Therapeutics Inc Company Profile
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric modulator for chronic oral dosing, including seizures in developmental and epileptic encephalopathies; and SAGE-319, an extrasynaptic-preferring GABA receptor positive allosteric modulator PAM for treating behavioral symptoms associated with neurodevelopmental disorders. In addition, the company is developing various product candidates, including SAGE-817 and SAGE-039 for the treatment of acute and chronic brain health disorders, including work on allosteric modulation of the GABA and NMDA receptor systems in the brain, as well as NMDA receptor negative allosteric modulator focusing on the treatments for neurodevelopmental disorders. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
SAGE Therapeutics Inc SWOT Analysis
Zurzuvae's Potential | Explore Sage Therapeutics' flagship product for postpartum depression, its early success, and the challenges in achieving profitability based on its sales alone |
Pipeline Setbacks | Delve into recent clinical trial failures, including dalzanemdor, and their impact on Sage's development strategy in the CNS drug market |
Financial Outlook | Analyst price targets range from $4 to $26, with revenue projections reaching $524 million by 2026, despite concerns over profitability and cash burn |
Strategic Pivot | Learn about Sage's focus on early-stage pipeline advancement and potential business development opportunities to rebuild investor confidence |
Compare SAGE to Peers and Sector
Metrics to compare | SAGE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSAGEPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.2x | −0.7x | −0.5x | |
PEG Ratio | −0.04 | −0.01 | 0.00 | |
Price/Book | 1.0x | 1.6x | 2.6x | |
Price / LTM Sales | 11.4x | 12.1x | 2.9x | |
Upside (Analyst Target) | 3.4% | 388.8% | 57.2% | |
Fair Value Upside | Unlock | 9.9% | 8.9% | Unlock |
Analyst Ratings
3 Buy
15 Hold
1 Sell
Ratings:
19 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 8.10
(+6.32% Upside)
Earnings
Latest Release
Feb 11, 2025
EPS / Forecast
-1.56 / -1.50
Revenue / Forecast
12.81M / 14.08M
FAQ
What Is the SAGE Therapeutics (SAGE) Stock Price Today?
The SAGE Therapeutics stock price today is 7.62
What Stock Exchange Does SAGE Therapeutics Trade On?
SAGE Therapeutics is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for SAGE Therapeutics?
The stock symbol for SAGE Therapeutics is "SAGE."
What Is the SAGE Therapeutics Market Cap?
As of today, SAGE Therapeutics market cap is 468.48M.
What is SAGE Therapeutics Earnings Per Share?
The SAGE Therapeutics EPS is -6.59.
What Is the Next SAGE Therapeutics Earnings Date?
SAGE Therapeutics will release its next earnings report on 28 Apr 2025.
From a Technical Analysis Perspective, Is SAGE a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.